Previous 10 | Next 10 |
WALTHAM, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2023 financial results on Wednesday, February 21, 2024. The Company will issue a press release before the market opens and will host a conference ca...
2024-01-26 12:23:42 ET More on Bio-Rad Labs, Danaher, etc. Thermo Fisher: Blue Chip Stock Melded With Growth Characteristics J.P. Morgan 42nd Annual Healthcare Conference Danaher Corporation (DHR) 42nd Annual JPMorgan Healthcare Conference (Transcript) Thermo...
2024-01-21 18:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-20 05:00:00 ET Summary NZS Capital is an investment company focused on adaptable, innovative businesses that work toward maximizing non-zero-sum (NZS, or win-win) outcomes for their investors, customers, employees, society, and the global environment. The flagship strategy...
2023-12-24 08:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
WALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 42 nd Annual J.P. Morgan Healthcare conference being held January 8-11 in San Francisco. To...
2023-12-15 16:09:56 ET Summary Today we take a deeper look at Repligen Corporation, a biologic manufacturer whose shares have rallied over 50% since late October. The rally seems overextended given both earnings and revenues are tracking to significant declines in FY2023. An a...
2023-12-07 07:57:53 ET More on Repligen Repligen Corporation (RGEN) Q3 2023 Earnings Call Transcript Repligen: Current Market Values Well Supported, Valuations Are Not, Reiterate Hold Repligen beats top and bottom line estimates, narrows FY guidance Repligen ...
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 0.375% Convertible Senior Notes due 2024 (the ȁ...
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “ Making...
News, Short Squeeze, Breakout and More Instantly...
U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Tuesday. Shares of HealthStream, Inc. (NASDAQ:HSTM) rose sharply duri...
Repligen Corporation (NASDAQ: RGEN) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 9.58% on the day to $172.57. Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biologic...
WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first qua...